What changes to pricing guidelines mean for drugs in Canada
After multiple delays, the PMPRB (Patented Medicine Prices Review Board) is expected to implement revised guidelines within 2022, which include an update to...
Ashley Fraser is a Principal in the Life Sciences Practice of Charles River Associates. She has nine years of experience advising pharmaceutical, biotech, and medical device organizations.
Her consulting experience includes pricing, reimbursement and market access strategies across the product development lifecycle, payer engagement, lifecycle management, and optimization of internal P&MA processes and team structures. Her engagements cover a range of therapeutic areas and emphasize Canada, US, and EU5 among other Global markets. Prior to her role at CRA, Ms. Fraser was an Associate Principal at QuintilesIMS.